Medicine shortages put patients at risk, MPs and peers warn
A new report from the All-Party Parliamentary Group (APPG) on pharmacy called for urgent action to ensure shortages do not become the 'new normal'.
It also highlights the impact that shortages are having on patients with the likes of ADHD (attention deficit hyperactivity disorder), menopause and diabetes.
Writing in the report, Steve Race, chairman of the APPG on pharmacy, said many MPs 'have received a growing volume of correspondence from constituents who are understandably anxious about the availability of their medicines'.
'Whether it is a parent unable to access antibiotics for a sick child, an elderly patient facing delays in obtaining life-sustaining medication, or a pharmacist overwhelmed by the need to source alternatives, the human impact is both visible and deeply troubling,' he wrote.
The report said that while medicine shortages are 'not a new phenomenon', they have 'become increasingly severe, persistent, and disruptive' in recent years – leading to consequences for patients, staff and the wider health service.
Mr Race said: 'Medicines shortages have moved from isolated incidents to a chronic structural challenge for both the NHS and pharmacy sector.
'As Government continues to recognise and invest in the expanded clinical role of community pharmacy, we must ensure the medicines supply chain underpinning that care is equally robust, resilient and patient-focused.
'Pharmacy is central to NHS recovery and transformation, but frontline teams cannot safely expand clinical services while daily supply disruptions continue to impact the health of patients.'
The findings also highlight how shortages severely impact patients with conditions like ADHD, menopause and diabetes.
More than nine in 10 pharmacists, GPs and prescribers told an APPG survey ADHD medicines had been affected by shortages.
Around three quarters (76%) said HRT and diabetes drugs had been affected, while 44% said antibiotics.
One patient with ADHD told the inquiry they had been self-medicating with cannabis due to an ongoing shortage of methylphenidate.
The report said: 'These shortages are having a significant impact on patients' ability to access treatments and in some cases are having serious impact on patients' health and well-being.'
Mr Race added: 'Medicines security must be treated as a core component of NHS planning, alongside funding, workforce and digital infrastructure.
'Failure to act risks further undermining patient care and destabilising a community pharmacy sector that millions depend upon.'
The APPG has laid out a number of recommendations, which includes a number of measures to better support patients.
People impacted by shortages, particularly those with chronic conditions, struggle to find information on out of stock drugs, leading to 'frustration, dangerous delays in care, and unnecessary anxiety and harm', it said.
It also welcomed work being carried out by the Department of Health and Social Care to potentially change pharmacist prescribing protocols to allow pharmacists to make dose and formulation changes during shortages.
Elsewhere, the inquiry found more than eight in 10 pharmacists face daily shortages, with many spending hours every day finding alternative treatment and communicating with distressed patients.
One told the APPG they are 'constantly firefighting'.
Reacting to the report, Henry Gregg, chief executive of the National Pharmacy Association (NPA), said: 'Pharmacy teams are under enormous pressure but are forced to spend hours hunting down stock for distressed and frustrated patients.
'It is particularly frustrating for pharmacists to be unable to meet a clear need when they have a perfectly safe and effective solution in their pharmacy already.
'MPs are right that it is madness to send someone back to their GP to get a prescription changed, and it risks a patient either delaying taking vital medication or forgoing it altogether, which poses a clear risk to patient safety.
'As the APPG says, the Government must allow pharmacists – who are highly trained health care practitioners – to use their professional judgment to supply an appropriate alternative medication when the prescribed version is unavailable.'
A Department of Health and Social Care spokesperson said: 'This government inherited ongoing global supply problems, but we have robust measures in place to mitigate disruption for patients.
'We are working to build the resilience of medicine supply chains and prevent future disruption as we get the NHS back on its feet.
'We have recently agreed an extra £617 million of funding over two years with Community Pharmacy England to support the sector and provide patients with more services closer to home as part of our 10 Year Health Plan.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
2 hours ago
- Daily Mail
EXCLUSIVE From pancreatitis to hair loss and premature ageing... top doctors reveal all the startling health risks of Mounjaro and other weight loss jabs - and the precautions you must take
More than 1.5 million people in the UK now use the new weight-loss jabs, according to latest estimates – with benefits for their physical and mental wellbeing. Indeed, people with diabetes who took the drugs (known as GLP-1 agonists) had a lower risk of developing 42 diseases including a 22 per cent lower risk of a cardiac arrest, according a recent study in Nature Medicine.
The Guardian
2 hours ago
- The Guardian
‘They're holding me up and helping me get through': why campus welfare is there whenever you need it
University can be a fun and exciting experience, but it can also be challenging in different ways. When Becca Tenney began her occupational therapy degree at the University of Salford in 2024, she wasn't sure she'd make it through the year. A history of hospital admissions for an eating disorder and depression had left her apprehensive. 'Things had got really bad,' she says. 'But I approached Salford, and they were amazing from the get-go. They put me in touch with my head of year, I've got extra time and extensions in place if I need them and if I'm having a bad day my lecturers check in on me.' Now, at the end of her first year at Salford, she is feeling optimistic. She loves her course and has made lots of friends in her cohort. 'It's like I've got a whole team behind me. They're holding me up and helping me get through.' Looking after the wellbeing of students has never been more important. Today, student welfare is no longer treated as an add-on, it is baked into the university experience. From managing mental health to coping with disability, flatmate fallouts or financial pressures, dedicated support is increasingly accessible and visible. 'Universities take the welfare of students very seriously,' says Nick Hillman, director of the Higher Education Policy Institute. There is growing demand for these services among young people and the sector is adapting. 'It is no longer a taboo subject,' he says. Manuel Souto-Otero, a professor at the University of Bristol's school of education, says: 'This is not an easy time to be a student.' Pressures are stacking up – part-time jobs, the cost-of-living crisis, long commutes and caring responsibilities. 'There are a lot of demands on young people in higher education.' Support often starts before freshers even set foot on campus. Prospective students can flag existing needs on their Ucas application or disclose them ahead of enrolment. Once on campus, personal tutors are often the first port of call. University websites typically offer plenty of guidance, and campuses are dotted with posters and social media campaigns signposting students towards help. At Northumbria University, a 24/7 team is in place to triage and respond to wellbeing queries. 'We've got a physical help desk, students can raise concerns via the portal or just pick up the phone,' says Vashti Hutton, director of student life and wellbeing. The University of Derby has a similar setup. 'Whether students are after a quick chat or in-depth support, we direct students to the help they need,' says Sarah Richardson, head of student services. These include drop-ins, workshops, apps, digital tools and one-to-one appointments. At Falmouth University, all staff are trained and expected to help students spot when they might be in need of support and to guide them to the right place. Group workshops are common on campuses and cover everything from study skills and time-management to dealing with low moods or digital burnout. Many of the workshops are recorded, so students can access them online. One-to-one counselling is widely available, as are group therapy sessions. 'Students are not alone. We want everyone to have a good time, and we're here to support that,' says Northumbria's Hutton. At Sheffield Hallam University, sessions are themed around common challenges such as managing emotions, low self-esteem and feeling overwhelmed. They're run in six groups of about 10 students, led by a psychotherapist or counsellor. It helps normalise experiences and enables students to realise they are not alone. Supportive WhatsApp groups often form out of these sessions, offering informal peer support that lasts beyond the final meeting. For those less inclined to talk, there are other options – art therapy, yoga for wellbeing, and more. Student-led initiatives are playing a growing role, too. Cameron Swann, a final-year building surveying student and member of the students' union at Sheffield Hallam, says one-to-one peer support can be a powerful first step. 'A lot of students feel their problems aren't serious enough for formal help. This gives you a chance to talk with someone who is on the same wavelength and it gets you out of the house. It can be a stepping stone to talking to a professional at a later stage.' At Northumbria, peer-to-peer services are backed by university infrastructure but run by students. 'We've got bookable rooms and drop-ins,' says Hutton. 'Peer advisers are trained to help refer you on if they have concerns.' The message from professionals is clear: don't wait for a crisis. Support services can get busy, and reaching out early can make all the difference. John Rimington Wilson, 18, has Duchenne muscular dystrophy and was anxious about starting his graphic design degree at Sheffield Hallam last year. But early conversations with staff were reassuring. 'Before I started, I met with my lecturer, and they talked me through everything,' he says. 'They made me feel really comfortable. The university is clued-up and I feel like I'm in good hands.' You can contact the mental health charity Mind by calling 0300 123 3393 or visiting For more guidance on the right course for you, check out the Guardian university league tables for 2025. The Guardian league tables for 2026 will be out on 13 September in print and online
Rhyl Journal
2 hours ago
- Rhyl Journal
‘Groundbreaking' drug could slow down progression of type 1 diabetes
Teplizumab, which is already approved in the US, trains the immune system to stop attacking pancreatic cells, delaying the need for insulin by an average of three years. With type 1 diabetes, the immune system attacks insulin-producing cells in the pancreas, meaning blood sugar levels are no longer regulated by the body. If blood sugar is too high or low, it can cause serious health problems and even death. People with type 1 therefore need daily insulin. Dentist and mother-of-two, Hannah Robinson, from Devon, is the first adult in the UK to try the drug in the hope it can delay the condition. She is having treatment at the Royal Devon University Healthcare NHS Foundation Trust after discovering during pregnancy she was in the early stages of developing type 1. A handful of people are being given the medicine on a case-by-case basis while it is reviewed for wider use on the NHS. The 36-year-old said: 'For me, this new drug offers more freedom and the chance to focus on my health before I have to start thinking differently and managing life as somebody needing daily insulin. 'This isn't just about what I eat or monitoring my glucose, it is also about having more control and not feeling defined by my condition. 'This treatment could potentially pave the way for a future cure for type 1 diabetes, which is incredible. I feel very lucky to be part of this.' The new drug teplizumab must be given at the earliest stage of the disease to be effective. Dr Nick Thomas, diabetes consultant and academic clinical lecturer at the University of Exeter, said: 'This new treatment represents a really exciting shift in how we manage type 1 diabetes. 'For the first time ever, we will be able to provide targeted treatment early enough in the process to alter the underlying immune process, aiming to slow down how quickly people need insulin. 'Approximately half of all type 1 diabetes cases develop in adulthood, and Hannah will be the first adult in the UK to receive this treatment. 'My hope is that in the future, we may be able to stop people with early type 1 diabetes from needing insulin at all.' Experts at the Royal Devon and the University of Exeter are using genetics and other testing to spot people at high risk of developing type 1 diabetes. The hope is more people could be offered the drug to delay type 1. Dr Lucy Chambers, head of research impact and communications at Diabetes UK, said: 'For people in the early stages of type 1 diabetes, teplizumab offers a groundbreaking opportunity to buy them precious extra years insulin-free. 'Right now, it's only available in research settings – and while the excitement is real, urgent work is still needed to ensure it reaches everyone who could benefit. 'That means securing a UK licence for teplizumab, establishing national screening programmes to identify people with early-stage type 1 diabetes before symptoms appear, and preparing the NHS to deliver this treatment at scale. 'Diabetes UK is proud to be at the forefront of these efforts – funding pioneering research and working closely with the NHS towards a future where immunotherapies become the first-line treatment for tackling the autoimmune attack at the root of type 1 diabetes.' Professor Richard Oram, consultant physician at the Royal Devon and professor at the University of Exeter, said: 'Excitingly, teplizumab is the first drug with the potential to delay type 1 diabetes, but needs to be given before clinical diagnosis due to high blood glucose. 'It is really important to find new and improved approaches for identifying individuals at elevated risk.'
